A study on the safety and efficacy of semaglutide in obese patients

A study on the safety and efficacy of semaglutide in obese patients - A study on the safety and efficacy of semaglutide in obese patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000053714

Enrollment

Registered

2024-02-27

Start date

2024-03-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsesity patients

Interventions

Semaglutide injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: 1. Severe anemia (Hb level < 10 g/dL) 2. Patients using implanted medical devices (such as pacemakers) 3. Patients with active malignant tumors 4. Participants for whom the principal investigator or collaborating investigator has deemed participation in this clinical study inappropriate 5. Pregnant women or women who may be pregnant

Design outcomes

Primary

Measure	Time frame
The change in body weight at 22-26 weeks after semaglutide.	—

Secondary

Measure	Time frame
The change in time in range (TIR, 70-180 mg/dL) The change in time below range (TBR, <70 mg/dL) The change in time below range (TBR, <54 mg/dL) The change in time above range (TAR, >180 mg/dL) The change in time above range (TAR, >240 mg/dL) The change in mean sensor glucose level by CGM The change in %CV (coefficient of variation) of sensor glucose level The change in SD (standard deviation) of sensor glucose level The change in glucose management indicator (GMI) The change in glycemia risk index (GRI) The change in the frequency of hypoglycemic events The change in HbA1c and glycated albumin The change in C-peptide index The change in the dosage of insulin The change in body composition (fat mass, muscle mass. lean body mass and waist circumference) The change in blood pressure The change in non-HDL cholesterol The difference in efficacy of semaglutide between patients with and without sleep apnea	—

Measure

Time frame

The change in time in range (TIR, 70-180 mg/dL) The change in time below range (TBR, <70 mg/dL) The change in time below range (TBR, <54 mg/dL) The change in time above range (TAR, >180 mg/dL) The change in time above range (TAR, >240 mg/dL) The change in mean sensor glucose level by CGM The change in %CV (coefficient of variation) of sensor glucose level The change in SD (standard deviation) of sensor glucose level The change in glucose management indicator (GMI) The change in glycemia risk index (GRI) The change in the frequency of hypoglycemic events The change in HbA1c and glycated albumin The change in C-peptide index The change in the dosage of insulin The change in body composition (fat mass, muscle mass. lean body mass and waist circumference) The change in blood pressure The change in non-HDL cholesterol The difference in efficacy of semaglutide between patients with and without sleep apnea

—

Countries

Japan

Contacts

Public ContactAkinori Hayashi

Kitasato University School of Medicine Department of Endocrinology, Diabetes and Metabolism

ahayashi@kitasato-u.ac.jp0427788111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026